Navigation path

Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

Allogeneic donor-derived ex-vivo expanded T lymphocytes transduced with a retroviral vector containing inducible caspase 9 and truncated CD19

EU orphan designation number: EU/3/16/1674   
Active ingredient: Allogeneic donor-derived ex-vivo expanded T lymphocytes transduced with a retroviral vector containing inducible caspase 9 and truncated CD19
Indication: Treatment in haematopoietic stem cell transplantation
Sponsor: Bellicum Pharma GmbH
Josephspitalstrasse 15, Altstadt-Lehel, 80331 Munich, Bavaria, Deutschland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
29/06/2016 Orphan designation EMA/OD/020/16 (2016)4115 of 27/06/2016
10/05/2017 Transfer of orphan designation EMA/OD/020/16/T/01 (2017)3191 of 8/05/2017
25/02/2019 Transfer of orphan designation EMA/OD/0000004083 (2019)1630 of 21/02/2019